Henry Schein furthers commitment to vaccine equity by partnering with the Black Coalition Against COVID-19
Henry Schein, Inc. (Melville, NY) announced its partnership with the Black Coalition Against COVID-19 (BCAC) in support of the BCAC’s recent virtual town hall, “Making It Plain: A COVID-19 Town Hall for Minority Health Professionals.”
Henry Schein says its collaboration with the BCAC reinforces the company’s advocacy for vaccine equity and the vital role primary-care physicians and other office-based healthcare practitioners play in expanding COVID-19 vaccinations nationwide.
Launched in 2020 by the BCAC, Making It Plain is a national-level series of educational, open-forum virtual town hall conversations led by senior government officials and leading minority health professionals on the epidemiology, prevention, treatment, and vaccination efforts for
COVID-19. Henry Schein has supported two of the BCAC’s Making It Plain events:
- December 17, 2020 – Making It Plain: Minority Health Professionals and COVID-19 Vaccine Dissemination
- March 23, 2021 – Making It Plain: A COVID-19 Town Hall for Minority Health Professionals
The latest town hall, “Making It Plain: A COVID-19 Town Hall for Minority Health Professionals,” emphasized the vital resource primary-care physicians are in the COVID-19 vaccination effort because of the high level of trust they have with their patients, their understanding of a patient’s health history, and their physical presence in every community across the country.
Ann Marie Gothard, VP of Global Corporate Media Relations at Henry Schein, spoke at the event, discussing the need for office-based partnerships in minority communities to have access to the vaccine and the opportunity to complement existing distribution efforts by ensuring that all health care providers – in close partnership with Community-based and Faith-based organizations – have ready access to vaccines to administer to their patients.
For the past several months, Henry Schein and the BCAC have partnered closely to determine recommendations and strategies to accelerate equitable access to the COVID-19 vaccine. Henry Schein supports a broad array of providers in a variety of settings, many of whom are frontline office-based and community health providers. Being close to this critical part of the healthcare infrastructure has given the company insights into the public health needs of underserved populations.
In addition to its participation with BCAC, Stanley Bergman, chairman of the board and CEO of Henry Schein, recently issued a statement of support for congressional efforts to expand COVID-19 vaccine distribution, highlighting these significant lags in vaccination rates, particularly in communities of color, rural communities, and among the elderly and disabled. The company continues to speak with government officials, calling for more effectively involving primary-care physicians and other office-based healthcare professionals in the vaccine dissemination process.
BD receives EUA for combo COVID-19, Flu A/B rapid antigen test
In late March, BD (Becton, Dickinson and Company) (Franklin Lakes, NJ) announced the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for a new, rapid antigen test that can detect SARS-CoV-2, influenza A and influenza B in a single test. The BD Veritor System for Rapid Detection of SARS-CoV-2 & Flu A+B assay takes about 15 minutes to run on the BD Veritor Plus System and distinguishes between SARS-CoV-2, influenza A and influenza B, by providing definitive positive or negative individual digital display readouts for all three. BD plans to launch the new test this summer for the 2021-2022 flu season.